HC Wainwright & Co. Initiates Coverage On Trevi Therapeutics with Buy Rating, Announces Price Target of $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Trevi Therapeutics with a Buy rating and set a price target of $6.
August 30, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Trevi Therapeutics with a Buy rating and a price target of $6, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $6 by HC Wainwright & Co. suggests a positive sentiment towards Trevi Therapeutics. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100